NCT04886804 · CITED IN SOURCE DOCUMENTS

Beamion LUNG-1: A Study to Test Different Doses of Zongertinib in People With Different Types of Advanced Cancer (Solid Tumours With Changes in the HER2 Gene)

An NCI or FDA source cites this study. A citation does not establish that it applies to an individual diagnosis.

Phase: PHASE1
Status at capture: ACTIVE NOT RECRUITING
Registry last update: 2026-08-20

The study has 2 parts. The first part is open to adults with different types of advanced cancer (solid tumours with changes in the HER2 gene) for whom previous treatment was not successful. The second part is open to people with non-small cell lung cancer with a specific mutation in the HER2 gene. The purpose of the first study part is to find the highest dose of a medicine called zongertinib the participants can tolerate. Once this dose is found, it will be used in the second study part to test whether zongertinib can make tumours shrink. In this study, zongertinib is given to people for the first time. Participants take zongertinib as tablets once a day or twice a day. The participants are in the study for as long as they benefit from and can tolerate treatment. Study doctors regularly check the participants' health and monitor the tumours. The doctors also take note of any unwanted effects that could have been caused by zongertinib.

Open the original ClinicalTrials.gov record → · Download preserved record

What did the study report?

Outcomes, safety and baseline populations are separate source sections. Quality-of-life measures appear under their original outcome titles.

No posted result sections were captured. Registered plans do not establish that a treatment works.

Who could take part

eligibility Criteria: Inclusion Criteria: * Histologically or cytologically confirmed diagnosis of an advanced, unresectable and/or metastatic non-haematologic malignancy. Patient must show presence of at least one measurable lesion according to Response Evaluation Criteria In Solid Tumors (RECIST) 1.1. * Eastern Cooperative Oncology Group (ECOG) score of 0, 1 or 2 (ECOG=2 only for Cohorts 6, 7 and 9) . * Availability and patient willingness to provide a sample of tumour for confirmation of the patient´s Human epidermal growth factor receptor 2 (HER2) status. This sample can be archival material obtained at any time prior to study enrollment. * Patient willing and able to comply with the protocol requirements for tumour biopsies (biopsies from brain metastases are not allowed). * Adequate organ function defined as all of the following: * Absolute neutrophil count (ANC) ≥ 1.5 x 10\^9/L (≥ 1.5 x 10\^3/μL) (≥ 1500/mm\^3); haemoglobin ≥ 9.0 g/dL (≥ 90 g/L) (≥ 5.6 mmol/L); platelets ≥ 100 x 10\^9/L (100 x 10\^3/μL) (100 x 10\^3/mm3) without the use of hematopoietic growth factors within 4 weeks of start of trial medication. * Total bilirubin ≤ 1.5 times the upper limit of normal (ULN), except for patients with Gilbert's syndrome: total bilirubin ≤ 3 x ULN or direct bilirubin ≤ 1.5 x ULN. * Estimated Glomerular Filtration Rate (eGFR) ≥ 50 mL/min - calculated using Chronic Kidney Disease Epidemiology (CKD-EPI) formula (≥ 30 mL/min/1.73m² for cohorts 6, 8, and 9). * Aspartate transaminase (AST) and alanine transaminase (ALT) ≤ 3 x ULN if no demonstrable liver metastases, or otherwise ≤ 5 x ULN if transaminase elevation is attributable to liver metastases. * Alkaline Phosphatase \< 5 x ULN. * Recovered from any previous therapy-related toxicity to ≤ Common Terminology Criteria for Adverse Events (CTCAE) Grade 1 at start of treatment (except for alopecia, stable sensory neuropathy and hypothyroidism (patients on thyroid replacement therapy) which must be ≤ CTCAE Grade 2) * Life expectancy of at least 12 weeks at the start of treatment in the opinion of the investigator. * At least 18 years of age at the time of consent or over the legal age of consent in countries where that is greater than 18 years. * Signed and dated written informed consent in accordance with International Council on Harmonisation-Good Clinical Practice (ICH-GCP) and local legislation prior to admission to the trial. * Male or female patients. Women of childbearing potential (WOCBP) and men who are able to father a child must be ready and able to use highly effective methods of birth control per International Council on Harmonisation (ICH) M3 (R2) that result in a low failure rate of less than 1% per year when used consistently and correctly. Additional inclusion criteria for Phase Ia * Patients with a documented diagnosis of HER2 aberration: overexpression OR gene amplification OR non-synonymous somatic mutation OR gene rearrangement involving HER2 or Neuregulin 1 (NRG1) * Patient who has failed conventional treatment or for whom no therapy of proven efficacy exists or who is not eligible for established treatment options. Patient must have exhausted, or not be a suitable candidate for, available treatment options known to prolong survival for their disease Additional inclusion criteria for Phase Ib - Cohort 1 only * Non-squamous non-small cell lung cancer (NSCLC) patients with documented human epidermal growth factor receptor 2 (HER2) mutation in the tyrosine kinase domain (TKD) as per local lab results. * Patient who had received, in the advanced/metastatic setting, at least one line of systemic therapy. Patients with non-squamous NSCLC harboring additionally genomic aberrations for which approved targeted therapy is available as standard of care. Additional inclusion criteria for Phase Ib - Cohort 2 only * Non-squamous NSCLC patient with a documented HER2 mutation in the tyrosine kinase domain (TKD) as per local lab results. * Treatment naïve for non-squamous NSCLC. Additional inclusion criteria for Phase Ib - Cohort 3 only * NSCLC Patient with a documented HER2 mutation outside of the tyrosine kinase domain (TKD) as per local lab results or squamous NSCLC patient with mutation in the TKD as per local lab results. * Patient who had received, in the advanced/metastatic setting, at least one line of systemic therapy. Patients with NSCLC harboring additionally genomic aberrations for which approved targeted therapy is available as standard of care. Additional inclusion criteria for Phase Ib - Cohort 4 only * NSCLC patients with documented HER2 mutation in the TKD as per local lab results. * NSCLC patients who are either treatment naïve or who had received any prior line of treatment, in the advanced/metastatic setting. Patients with NSCLC harboring additional genomic aberrations for which approved targeted therapy is available as standard of care. * Patient with active brain metastases who are not eligible for immediate local therapy, as per investigator evaluation. Additional inclusion criteria for Phase Ib - Cohort 5 only * Non-squamous NSCLC patients with documented HER2 mutation in the TKD as per local lab results. * Patient should have received, in the advanced/metastatic setting, at least one line of systemic therapy that includes a platinum-based combination chemotherapy and should have been treated with previous HER2 directed antibody-drug conjugates (ADC) in the same advanced/metastatic setting and developed disease progression recurrence during or after completing this therapy. Patients with NSCLC harboring additional genomic aberrations for which approved targeted therapy is available as standard of care. Additional inclusion criteria for Phase Ib - Cohort 6 only * Non-squamous NSCLC patient with documented HER2 mutation in the TKD as per local lab results. * Patient who had received, in the advanced/metastatic setting, at least one line of systemic therapy. * Patient without active brain metastases or patient with active brain metastases who are not eligible for immediate local therapy, as per investigator evaluation. * Patient who is not eligible for any other recruiting cohort. Additional inclusion criteria for Phase Ib - Cohort 7 only * Non-squamous NSCLC patient with documented HER2 mutation in the TKD as per local lab results. * Patient who had received, in the advanced/metastatic setting, at least one line of systemic therapy. * Patient without active brain metastases or patient with active brain metastases who are not eligible for immediate local therapy, as per investigator evaluation. * Patient who is not eligible for any other recruiting cohort. Additional inclusion criteria for Phase Ib - Cohort 8 only * Treatment naïve for NSCLC * NSCLC (adenocarcinoma or squamous) patient with documented HER2 mutation in the tyrosine kinase domain (TKD) or non-squamous NSCLC with a documented HER2 mutation in the non tyrosine kinase domain (non TKD) as per local lab results Additional inclusion criteria for Phase Ib - Cohort 9 only * Non-squamous NSCLC patient with documented HER2 mutation in the TKD as per local lab results. * Patient who had received, in the advanced/metastatic setting, at least one line of systemic therapy. Patients with NSCLC harboring additionally genomic aberrations for which approved targeted therapy is available as standard of care. Further inclusion criteria apply. Exclusion Criteria: * Major surgery (major according to the investigator's assessment) performed within 4 weeks prior to first trial treatment or planned within 6 months after screening * Previous or concomitant malignancies other than the one treated in this trial within the last 2 years, except: * effectively treated non-melanoma skin cancers * effectively treated carcinoma in situ of the cervix * effectively treated ductal carcinoma in situ * other effectively treated malignancy that is considered cured by local treatment. * Treatment with a systemic anti-cancer therapy or investigational drug within 21 days or 5 half-lives (whichever is shorter) of the first treatment with the study medication * Patients who must or wish to continue the intake of restricted medication or any drug considered likely to interfere with the safe conduct of the trial * Previous treatment with zongertinib. * Radiotherapy within 2 weeks prior to first study treatment, except palliative radiotherapy to regions other than the chest, which is allowed up to 1 week prior to first study treatment. Further exclusion criteria apply.
healthy Volunteers: false
minimum Age: 18 Years
sex: ALL
std Ages: ADULT
OLDER_ADULT

Treatment arms and interventions

arm Groups

description
Consecutive cohorts of patients treated with escalating doses of BI 1810631 monotherapy.
intervention Names
Drug: zongertinib
label
Phase Ia - Dose escalation part
type
EXPERIMENTAL
intervention Names
Drug: zongertinib
label
Phase Ib - Dose expansion part: Cohort 1
type
EXPERIMENTAL
intervention Names
Drug: zongertinib
label
Phase Ib - Dose expansion part: Cohort 2
type
EXPERIMENTAL
intervention Names
Drug: zongertinib
label
Phase Ib - Dose expansion part: Cohort 3
type
EXPERIMENTAL
intervention Names
Drug: zongertinib
label
Phase Ib - Dose expansion part: Cohort 4
type
EXPERIMENTAL
intervention Names
Drug: zongertinib
label
Phase Ib - Dose expansion part: Cohort 5
type
EXPERIMENTAL
description
Cohort only in the United States of America (USA)
intervention Names
Drug: zongertinib
label
Phase Ib - Dose expansion part: Cohort 6
type
EXPERIMENTAL
description
Cohort only in Japan
intervention Names
Drug: zongertinib
label
Phase Ib - Dose expansion part: Cohort 7
type
EXPERIMENTAL
description
Cohort only in the United States of America (USA)
intervention Names
Drug: zongertinib
label
Phase Ib - Dose expansion part: Cohort 8
type
EXPERIMENTAL
description
Cohort only in China
intervention Names
Drug: zongertinib
label
Phase Ib - Dose expansion part: Cohort 9
type
EXPERIMENTAL

interventions

arm Group Labels
Phase Ia - Dose escalation part
Phase Ib - Dose expansion part: Cohort 1
Phase Ib - Dose expansion part: Cohort 2
Phase Ib - Dose expansion part: Cohort 3
Phase Ib - Dose expansion part: Cohort 4
Phase Ib - Dose expansion part: Cohort 5
Phase Ib - Dose expansion part: Cohort 6
Phase Ib - Dose expansion part: Cohort 7
Phase Ib - Dose expansion part: Cohort 8
Phase Ib - Dose expansion part: Cohort 9
description
zongertinib
name
zongertinib
other Names
BI 1810631, Hernexeos®
type
DRUG

Study design

allocation

NON_RANDOMIZED

intervention Model

SEQUENTIAL

masking Info

masking: NONE

primary Purpose

TREATMENT

Enrollment

count: 554
type: ESTIMATED

Registered outcome plans (not posted results)

primary Outcomes

description
Maximum tolerated dose is defined as the highest dose with less than 25% risk of the true Dose Limiting Toxicity (DLT) rate being equal to or above 33% during the MTD evaluation period in any studied regimen.
measure
Phase Ia: Maximum Tolerated Dose (MTD)
time Frame
At the end of Cycle 1 (each cycle is 21 days).
measure
Phase Ia: Number of patients with Dose Limiting Toxicities (DLTs) in the MTD evaluation period
time Frame
At the end of Cycle 1 (each cycle is 21 days).
description
OR is defined as best overall response of complete response (CR) or partial response (PR), where best overall response is determined according to Response Evaluation Criteria In Solid Tumors (RECIST) version 1.1, from the first treatment administration until the earliest of disease progression, death or last evaluable tumor assessment before start of subsequent anticancer therapy, loss to follow-up or withdrawal of consent.
measure
Phase Ib - Cohorts 1, 2 and 5 : Objective response (OR) as assessed by central independent review
time Frame
From the start of the trial treatment until end of month 12, up to 12 months.
measure
Phase Ib - Cohorts 3, 6, 7, 8, and 9: Objective response according to RECIST 1.1 by investigator assessment
time Frame
From the start of the trial treatment until end of month 12, up to 12 months.
measure
Phase Ib: Cohort 4: Objective response according to Response Assessment in Neuro-Oncology for Brain Metastases (RANO-BM) by central independent review
time Frame
From the start of the trial treatment until end of month 12, up to 12 months.

secondary Outcomes

measure
Phase Ia: Number of patients experiencing DLTs during the entire treatment period
time Frame
From the start of the trial treatment until end of month 8, up to 8 months.
measure
Phase Ia: Maximum measured concentration of zongertinib in plasma (Cmax)
time Frame
On day 1 and on day 15 of Cycle 1 (each cycle is 21 days).
measure
Phase Ia: Area under the concentration-time curve of zongertinib in plasma (AUC0-t2)
time Frame
On day 1 and on day 15 of Cycle 1 (each cycle is 21 days).
description
DoR is defined as the time from first documented complete response (CR) or partial response (PR) until the earliest of disease progression or death among patients with objective response as assessed by central independent review.
measure
Phase Ib - Cohorts 1, 2 and 5: Duration of objective response (DoR) according to RECIST 1.1
time Frame
From the start of the trial treatment until end of month 12, up to 12 months.
description
DC is defined as best overall response of complete response (CR) or partial response (PR) or stable disease (SD) where best overall response is defined according to RECIST version 1.1 as assessed central independent review, from first treatment administration until the earliest of disease progression, death or last evaluable tumor assessment before start of subsequent anti-cancer therapy, loss to follow-up or withdrawal of consent.
measure
Phase Ib - Cohorts 1, 2 and 5: Disease control (DC)
time Frame
From the start of the trial treatment until end of month 12, up to 12 months.
description
PFS is defined as the time from first treatment administration until tumor progression according to RECIST version 1.1 as assessed by central independent review, or death from any cause, whichever occurs earlier.
measure
Phase Ib - Cohorts 1, 2 and 5: Progression-free survival (PFS)
time Frame
From the start of the trial treatment until end of month 12, up to 12 months.
measure
Phase Ib - Cohorts 1, 2 and 5: Objective response according to response assessment in neuro-oncology for brain metastases (RANO-BM) criteria as assessed by central independent review for patients with central nervous system (CNS) lesions at baseline
time Frame
From the start of the trial treatment until end of month 12, up to 12 months.
measure
Phase Ib - Cohorts 1, 2 and 5: Disease control according to RANO-BM criteria as assessed by central independent review for patients with CNS lesions at baseline
time Frame
From the start of the trial treatment until end of month 12, up to 12 months.
measure
Phase Ib - Cohorts 1, 2 and 5: Objective response according to RECIST 1.1 criteria as assessed by central independent review
time Frame
From the start of the trial treatment until end of month 12, up to 12 months.
measure
Phase Ib - Cohorts 1, 2 and 5: Disease control according to RECIST 1.1 criteria as assessed by central independent review
time Frame
From the start of the trial treatment until end of month 12, up to 12 months.
measure
Phase Ib - Cohorts 3, 6, 7, 8 and 9: Duration of objective response according to RECIST 1.1 by investigator assessment
time Frame
From the start of the trial treatment until end of month 12, up to 12 months.
measure
Phase Ib - Cohorts 3, 6, 7, 8 and 9: Disease control according to RECIST 1.1 as assessed by the investigator
time Frame
From the start of the trial treatment until end of month 12, up to 12 months.

Full study description

brief Summary: The study has 2 parts. The first part is open to adults with different types of advanced cancer (solid tumours with changes in the HER2 gene) for whom previous treatment was not successful. The second part is open to people with non-small cell lung cancer with a specific mutation in the HER2 gene. The purpose of the first study part is to find the highest dose of a medicine called zongertinib the participants can tolerate. Once this dose is found, it will be used in the second study part to test whether zongertinib can make tumours shrink. In this study, zongertinib is given to people for the first time. Participants take zongertinib as tablets once a day or twice a day. The participants are in the study for as long as they benefit from and can tolerate treatment. Study doctors regularly check the participants' health and monitor the tumours. The doctors also take note of any unwanted effects that could have been caused by zongertinib.

Source references

references

citation
Heymach JV, Yamamoto N, Girard N, Ruiter G, Smit EF, Planchard D, Nadal E, Wu YL, Zugazagoitia J, Tu HY, Baik CS, Yoh K, Soo RA, Zhao Y, Sabari JK, Wermke M, Scheffler M, Ahn MJ, Fernamberg K, Schroeter L, Sadrolhefazi B, Thamer C, Eigenbrod-Giese S, Popat S; Beamion LUNG-1 Investigators. First-Line Zongertinib in Advanced HER2-Mutant Non-Small-Cell Lung Cancer. N Engl J Med. 2026 Apr 30;394(17):1675-1684. doi: 10.1056/NEJMoa2516969. Epub 2026 Apr 15.
pmid
41985129
type
DERIVED
citation
Heymach JV, Ruiter G, Ahn MJ, Girard N, Smit EF, Planchard D, Wu YL, Cho BC, Yamamoto N, Sabari JK, Zhao Y, Tu HY, Yoh K, Nadal E, Sadrolhefazi B, Rohrbacher M, von Wangenheim U, Eigenbrod-Giese S, Zugazagoitia J; Beamion LUNG-1 Investigators. Zongertinib in Previously Treated HER2-Mutant Non-Small-Cell Lung Cancer. N Engl J Med. 2025 Jun 19;392(23):2321-2333. doi: 10.1056/NEJMoa2503704. Epub 2025 Apr 28.
pmid
40293180
type
DERIVED
citation
Heymach JV, Opdam F, Barve M, Tu HY, Wu YL, Berz D, Schroter L, Botilde Y, Sadrolhefazi B, Serra J, Yoh K, Yamamoto N. HER2-Selective Tyrosine Kinase Inhibitor, Zongertinib (BI 1810631), in Patients With Advanced/Metastatic Solid Tumors With HER2 Alterations: A Phase Ia Dose-Escalation Study. J Clin Oncol. 2025 Apr 10;43(11):1337-1347. doi: 10.1200/JCO-24-01727. Epub 2025 Mar 3.
pmid
40030100
type
DERIVED
citation
Heymach J, Opdam F, Barve M, Gibson N, Sadrolhefazi B, Serra J, Yamamoto N. A Phase I, Open-Label, Dose Confirmation, Escalation, and Expansion Trial of BI 1810631 as Monotherapy in Patients With Advanced or Metastatic Solid Tumors With HER2 Aberrations. Clin Lung Cancer. 2023 Mar;24(2):e65-e68. doi: 10.1016/j.cllc.2022.10.008. Epub 2022 Nov 11.
pmid
36528522
type
DERIVED